ZGC GROUP’s Investee GenAns Biotech Receives U.S. FDA Approval for Clinical Trials for GA002


  • HOME

  • 2026-11-11

  • click:

  • Font size:bigmediumsmall

Recently, GA002 injection, a chemogenetics-based precision modulation therapy independently developed by GenAns Biotech, a direct investee of ZGC GROUP, together with its associated brain-parenchymal injection device, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), paving the way for Phase I/II clinical trials in the United States. Previously, GA002 received approval from China’s National Medical Products Administration (NMPA) for a Phase I clinical trial of gene therapy for drug-resistant epilepsy, which has been initiated at Beijing Xuanwu Hospital.

IND authorization marks a key milestone in the international development of an innovative drug. The approval for GA002 indicates that U.S. regulators have recognized the preclinical research basis and overall development strategy of its original approach, which combines chemogenetic regulation, molecular-vector delivery, and targeted intracranial administration. GA002 has now been cleared for clinical trials in humans in the United States.

GenAns Biotech is a biomedicine enterprise focused on developing innovative gene therapy solutions for neurological disorders. Since the establishment, ZGC Capital, a subsidiary of ZGC GROUP, has led its angel round financing and actively assisted the company in connecting with industry resources, thereby injecting momentum into its early-stage R&D and operations.